OBJECTIVE： To observe the clinical efficacy and safety of pregabalin assisting anti-histamine drugs in the treatment of secondary skin pruritus in uremic patients underwent maintenance hemodialysis. METHODS： 140 uremic patients with secondary skin pruritus underwent maintenance hemodialysis were randomly divided into control group and treatment group， with 70 cases in each group. Control group was given loratadine orally， 10 mg， qd. Treatment group was additionally given pregabalin on the basis of control group， 75 mg， po， at night of hemodialysis end， increasing by 75 mg every week if no obvious relief was found， maximal dose of 300 mg. Both group received 3 months of treatment. Clinical efficacy， VAG itching score， modified Duo score， PSQI score before and after treatment and the incidence of ADR were compared between 2 groups. RESULTS： Total effective rate of treatment group （90.00％） was significantly higher than that of control group （71.43％）， with statistical significance （P＜0.05）； VAG itching score， modified Duo score and PSQI score of treatment group after treatment were significantly lower than control group and before treatment， with statistical significance （P＜0.05）. There was no significant difference in the incidence of ADR between 2 groups（P＞0.05）. CONCLUSIONS： Pregabalin assisting anti-histamine drugs in the treatment of secondary skin pruritus in uremic patients with maintenance hemodialysis can efficiently relieve the itching symptoms， improve sleep quality， and not increase the risk of ADR.